

DAFTAR PUSTAKA

1. Astor BC, Muntner P, Levin A. Association of kidney function with anemia : the third national health and nutrition examination survey (1988-1994). Arch Intern Med. 2002 ; 162:1401–8.
2. Riset Kesehatan Dasar (Riskesdas) (2018). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018. https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf. – Diakses September 2021.
3. Ble A, Fink JC, Woodman RC. Renal function, erythropoietin, and anemia of older persons: the in CHIANTI study. Arch Intern Med. 2005 ; 165: 2222–7.
4. Ratcliffe PF, Schofield C. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004 ; 5:343–354.
5. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006 ; 17:17–25.
6. Thomas MC, Tsalamandris C, MacIsaac R. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 2004 ; 66:1167–1172.
7. Bowling CB, Inker LA, Gutierrez OM, Allman RM, Warnock DG. Age specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol. 2011;6:2822.
8. Limori S, Naito S, Noda Y. Anemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: the CKD- ROUTE study. Nephrology (Carlton).2015;20:601–8.
9. Van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. J Med Econ. 2010;13:241–256.
10. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T. Health related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(1):33–8.

11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. *Am J Kidney Dis.* 2012;47:S11–S145.
12. Locatelli F, Aljama P, Barany P. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. *Nephrol Dial Transplant.* 2004;19:1–47.
13. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. *J Am Soc Nephrol.* 2002;13:504–10.
14. Jodie L, Babitt YL, Herbert YL. Mechanisms of anemia in chronic kidney disease. *J Am Soc Nephrol.* 2012; 23: 1631–4.
15. McClellan W, Aronoff SL, Bolton WK. The prevalence of anemia in patients with chronic kidney disease. *Curr Med Res Opin.* 2004;20:150.
16. Macdougall IC, Cooper AC. Erythropoietin resistance: role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant.* 2002;17:39–43.
17. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood.* 2003;102:783–88.
18. Donnelly S. Why is erythropoietin made in the kidney? the kidney functions as a critmeter. *Am J Kidney Dis.* 2001;38:415–25.
19. Palis J. Primitive and definitive erythropoiesis in mammals. *Front Physiol.* 2014;5:3.
20. Nemeth E, Tuttle MS, Powelson J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing internalization. *Science.* 2004;306:2090–93.
21. Saul N. Anemia in chronic kidney disease: causes, diagnosis, treatment. *Cleveland Clin J Med.* 2006;73:289–97.
22. Katevetin P, Miyata T, Inagi R. High glucose blunts VEGF response to hypoxia via the oxidative stress-regulated HIF-HRE pathway. *J Am Soc Nephrol.* 2006 ; 17:1405–1413.
23. Bonomini M, Siroli V: Uremic toxicity and anemia. *J Nephrol.* 2003 ; 16:21–28.

24. Eschbach JW, Adamson JW, Cook JD. Disorders of red blood cell production in uremia. *Arch Intern Med.* 2010 ; 126:812–15.
25. Radtke HW, Frei U, Erbes PM. Improving anemia by hemodialysis: effect on serum erythropoietin. *Kidney Int.* 2010 ; 17:382–7.
26. Gotloib L, Silverberg DS, Fudin R. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. *J Nephrol.* 2006 ;19:161–7.
27. Stenvinkel P, Ketteler M, Johnson RJ. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. *Kidney Int.* 2005 ; 67:1216–33.
28. Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. *Eur J Clin Invest.* 2005; 35:32–5.
29. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. *Am J Kidney Dis.* 2007 ; 29:565–8.
30. Goicoechea M, Martin J, de Sequera P. Role of cytokines in the response to erythropoietin in hemodialysis patients. *Kidney Int.* 2008 ; 54: 1337–43.
31. Cooper AC, Mikhail A, Lethbridge MW. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. *J Am Soc Nephrol.* 2003 ; 14:1776–84.
32. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DM, Levey AS, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. *J Am Soc Nephrol* 2005;16:1803–10.
33. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. *Am J Kidney Dis.* 2001;38:443–64.
34. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. *Nephrol Dial Transplant* 2005;20(10):2146–52.

35. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. *Clin Nephrol* 2005;64(2):113–23.
36. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. *Nephrol Dial Transplant*. 2004;19(4):898–903.
37. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. *Lancet*. 2006;368:947–53.
38. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, Mc Allister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. *J Am Soc Nephrol* 2006;17(4):1181–91.
39. Frank H, Heusser K, Hoffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. *Kidney Int*. 2004;66(2):832–40.
40. Miyashita K, Tojo A, Kimura K, Suzuki N, Mise N, Konno Y, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. *Hypertens Res*. 2004;27(2):79–84.
41. Pinto JP, Ribeiro S, Pontes H. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBP α . *Blood*. 2008;111:5727–33.
42. Adamson J. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation. *Adv Chronic Kidney Dis*. 2009;16(2):76–82.
43. Hodges VM, Rainey S, Lappin TR, Maxwell. Pathophysiology of anemia and erythrocytosis. *Crit Rev Oncol Hematol*. 2007;64:139 – 158.
44. Nijhof W, Wierenga PK, Sahr K, Beru N, Goldwasser E. Induction of globin mRNA transcription by erythropoietin in differentiating erythroid precursor cells. *Exp Hematol*. 2007; 15: 779–83.
45. Bissonnette RP, Rungta D, Hudson AR, Roach SL, Hong MH, Sun H, et al. Non-peptidyl small molecule EPO receptor agonists are potent pathway selective inducers of erythropoiesis. *Blood*. 2010 ;116 (21) : 1565.

46. Jelkmann, W. Erythropoietin: structure, control of production, and function. *Physiol Rev*, 2002 ;72: 449–489.
47. Christina E. Lankhorst , Jay B. Wish. Anemia in renal disease: diagnosis and management. *Blood*. 2010 ; 39–47.
48. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. *Nephrol Dial Transplant* 2003;18(2):353–61.
49. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med*. 2006;355(20):2085–98.
50. Szczech LA, Burnhart HXS, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. *Kidney Int* 2008;74:791–8.
51. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. *Am J Physiol Regul Integr Comput Physiol*. 2004;286:R977–88.
52. I. C. Macdougall. *Pocket Reference to Renal Anemia*. Springer Healthcare. 2013; 49-61.
53. Santos E.J.F, Hortegal E.V, Serra H.O, Lages J.S, Salgado and A. M dos Santos. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease : a longitudinal study. *Braz J Med Biol Res*. 2018;51:7288.
54. Weiss G, Ganz T and Lawrence T. Anemia of inflammation. *Blood*. 2019;133.
55. Sundhir N, Joshi S, Adya C M, Sharma R, Garg H. Profile of anemia in chronic kidney disease patients at a rural tertiary care centre : a prospective observational study. *IJCMR*. 2018;5:30–33.
56. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int*. 2012;2:283–7.
57. Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadani R. Soluble erythropoietin receptor contributes to erythropoietin resistance in end stage renal disease. *PloS One*. 2010;5:9246.

58. Westphal G, Braun K, Debus J. Detection and quantification of the soluble form of the human erythropoietin receptor in the growth medium of tumor celllines and in the plasma of blood samples. *Clin Exp Med*. 2002;2(1): 45-52.
59. Perhimpunan Nefrologi Indonesia (PERNEFRI). *Konsensus Manajemen Anemia pada Penyakit Ginjal Kronik*. Jakarta: PERNEFRI; 2011.
60. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. *CMRO*. 2004;20:1501–10.
61. Van der putten K, Braam B, Jie K E, Gaillard C. Mechanism of disease : erythropoietin resistance in patients with both heart and kidney failure. *Nat Clin Pract Nephrol*. 2008;4(1):47–57.
62. Hardiyanty N, Rini S L S, Arfian N. *Ekspresi eritropoietin, reseptor eritropoietin dan konsentrasi hemoglobin pada mencit gagal ginjal kronik*. [Tesis]. Yogyakarta: Ilmu Kedokteran Dasar dan Biomedis Universitas Gajah Mada. 2006.
63. Tamsil Y, Moeis ES, Wantania F. *Gambaran anemia pada subjek penyakit ginjal kronik stadium 4 dan 5 di poliklinik ginjal hipertensi RSUP Prof Dr.R.D Kandou*. *e-CliniC*. 2020;8(1):60–66.
64. Sang RR, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH, Sung S, et al. The prevalence and management of anemia in chronic kidney disease patients : result from the Korean cohort study for outcomes in patients with chronic kidney disease. *J Korean Med Sci*. 2017;32(2):249–256.
65. Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, Boffa JJ, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. *Clin J Am Soc Nephrol*. 2012;7: 35–42
66. Sarwana S. *Hubungan penyakit ginjal kronik dengan anemia pada pasien rawat inap RSUD Palembang*. *SJM*. 2014; 14-9.
67. Wika H. *Pengaruh penyakit ginjal kronik terhadap anemia pada pasien penyakit ginjal kronik*. *SJM*. 2014; 20-27.
68. Rosdah A. *Karakteristik pasien penyakit ginjal kronik di Rumah Sakit M Hoesin Palembang*. *SJM*. 2010;124-9.

69. Singh AK, Farag YMK, Mittal B V, Subramanian KK, Reddy ARK, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India. *BMC Nephrol.* 2013;14:114.
70. Kuspuji T, Suhardjono, Soewondo P, Shatri H. Renal function decrement in type 2 diabetes mellitus patients in Cipto Mangunkusumo Hospital. *Acta Med Indones.* 2008;40(4).
71. Salsabila N. Hubungan kadar ureum dan kadar hemoglobin pada pasien PGTA. [Tesis]. Semarang : Fakultas Kedokteran Universitas Diponegoro. 2019.
72. Hidayat R, Azmi S, Pertiwi D. Hubungan kejadian anemia dengan penyakit ginjal kronik pada pasien yang dirawat di bagian ilmu penyakit dalam RSUP dr M Djamil Padang tahun 2010. *JKA.* 2016;5(3).
73. Garini A. Kadar hemoglobin pada pasien gagal ginjal kronik yang menjalani hemodialisis. *SJM.* 2018;13(2).
74. Panjeta M, Tahirovic, Sofic E, Coric J, Dervisevic A. Interpretation of erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. *J Med Biochem.* 2017;36:145–152.
75. Agustina W, Wardani EK. Penurunan hemoglobin pada penyakit ginjal kronik setelah hemodialisis di RSUD Batu. *JKB.* 2019; 6(2):142–7.
76. Chang WZ, Chu HT, Yang CS, Chen CC. The factors of chronic kidney disease : diabetes, hypertension, smoking, drinking, betelnut chewing. *MDPI.* 2008;75–79.
77. Abboud, H and W.L Henrich. Stage V Chronic kidney disease. *N Eng J Med.* 2010 ;362:56–57.
78. Chanban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn T, Zimmet PZ. Prevalence of kidney damage in Australian adults. The AusDiab Kidney Study. *Jam Soc Nephrol.* 2003;14:131–8.
79. Natalia D, Susilawati, Safyudin. Hubungan laju filtrasi glomerulus dengan derajat anemia pada pasien penyakit ginjal kronik. *SJM* 2019;2:168–177.
80. Maria TW, Probowati W, Sugianto. Hubungan penurunan laju filtrasi glomerulus dengan derajat anemia pada pasien penyakit ginjal kronik. [Tesis]. Yogyakarta : Fakultas Kedokteran Universitas Gajah Mada. 2018.

81. Ayu NP, Suega K, Widiani GR. Hubungan antara beberapa parameter anemia dan laju filtrasi glomerulus pada penyakit ginjal diabetes pre dialysis. J Peny Dalam. 2010;11:3.

